Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-08-08 Capital/Financing Update
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
US$45 Million Private Placement to Major Shareholders 2 pages 164.9KB
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the completion of a US$45 million private placement financing by Mesoblast Limited. It details the amount raised, the number of shares issued, the price per share, and the intended use of proceeds. There is no financial statement or detailed financial report included, nor is there a mention of an attached or forthcoming report. The content focuses on capital raising activities and shareholder participation. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report publication or regulatory filing.
2022-08-08 English
Appendix 3B 57 pages 677.0KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard form used by entities listed on the Australian Securities Exchange (ASX) to announce a proposed issue of securities. It includes detailed information about the entity, the type of securities to be issued, and the conditions and timetable for the issue. The document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising activities. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is substantial and contains detailed information about the proposed securities issue, confirming it is not merely a brief announcement or a report publication notice.
2022-08-08 English
Voluntary Suspension 3 pages 229.0KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Mesoblast Limited regarding a voluntary suspension of trading of its shares on the ASX due to an ongoing capital raising. It references ASX Listing Rule 17.2 and details the reasons and expected duration of the suspension. There is no financial data, report content, or detailed financial analysis present. The document is short (2667 characters) and serves as an official announcement about a trading suspension related to capital raising activities. This fits the category of Capital/Financing Update (CAP) because it concerns updates on company fundraising and capital structure changes, specifically the suspension pending a capital raising announcement.
2022-08-07 English
6-K
Regulatory Filings
2022-08-05 English
Pause in Trading 1 page 111.3KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (341 characters) and does not contain any financial data, report content, or detailed information. It is an announcement related to trading status rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-03 English
Trading Halt 2 pages 213.2KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Mesoblast Limited regarding a trading halt requested pending an announcement about a proposed private placement. It references ASX Listing Rule 17.1 and states the halt is until an announcement is made or trading resumes. There is no financial data, report, or detailed analysis included. The document is short (2137 characters) and serves as a notification about a trading halt related to upcoming financing activity. This fits the category of Capital/Financing Update (CAP) as it concerns a private placement and trading halt related to capital raising.
2022-08-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.